Skip to main content
Fig. 5 | BMC Health Services Research

Fig. 5

From: Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China

Fig. 5

Estimates of net social value under three targeted approaches to lipid and blood pressure management. Notes: The three targeted approaches to lipid and blood pressure management include (i) treating all those with hyperlipidemia with a measure of LDL-C >130 mg/dL, and/or hypertension with SBP > 140 mmHg who had at least one other CVD risk factor; (ii) treating all with a measure of LDL-C >130 mg/dL (and/or SBP > 140 mmHg) and ages 55 years or older; and (iii) treating all with a measure of LDL-C >130 mg/dL (and/or SBP > 140 mmHg) and ages 65 years or older. Data are based on authors’ calculations. The assumed value of a life year in China is estimated at $13,408 (twice the GDP per capita in 2015). Approximately 23 % of the above estimates accrued between 2016 and 2020 and 55 % accrued between 2016 and 2025

Back to article page